·PIB

3rd DHR-ICMR Health Research Excellence Summit Brings Together Over 600 Scientists, Researchers and Policymakers in New Delhi

FlashcardsQuick reviseKey facts. One by one.Start →
In this note
  1. At a Glance
  2. Why in the News
  3. Background & Evolution
  4. Core Static Facts
  5. Multi-Dimensional Analysis
  6. Recent Developments (last 12-18 months)
  7. Prelims Hooks
  8. What the 100-Deal Number Does Not Tell Us
  9. Exclusive or Non-Exclusive: The Choice That Sets the Price
  10. The Strongest Case Against Selling Public Patents, and an Honest Answer
  11. Big New Tasks, Same Short-Staffed Labs
  12. Why India's Disease Data Still Sits in Separate Boxes
  13. What DHR, ICMR and the Health Ministry Should Do Next
  14. Anchors for Answers
  15. Mains Relevance
  16. Related Topics to Study Next
  17. NCERT Concepts to Revise
  18. Common Errors / Trap Areas

1. At a Glance

  • The 3rd DHR-ICMR Health Research Excellence Summit was held on 16-17 November 2026 in New Delhi. It brought together over 600 scientists, researchers and policymakers [1].
  • Headline result: ICMR passed 100 successful technology transfer deals under its Medical Innovations Patent Mitra initiative, less than 2 years after the initiative was launched [1].
  • The summit launched three initiatives, including the Research to Action Vertical of DHR and syndromic surveillance under the DHR VRDL Scheme. It also marked ICMR's 115 years [1].
  • Why it matters for UPSC: it covers health-research governance (DHR and ICMR), commercialisation of public R&D (moving from lab to market), outbreak preparedness after COVID, AMR, and scientific temper (Article 51A(h)).

2. Why in the News

  • At the summit (16-17 Nov 2026), ICMR announced it had crossed 100 cumulative technology transfer deals [1].
  • At the ceremony, 20 licensing agreements covering 8 technologies with 9 Indian companies were exchanged [1].
  • New initiatives: the Research to Action Vertical of DHR, syndromic surveillance across 70 VRDLs and IRDLs, and the ICMR AMR Annual Report and Standard Operating Procedures [1].
  • Anniversaries marked: 115 years of ICMR and the Golden Jubilee (50 years) of ICMR-NIMR, the National Institute of Malaria Research [1].

3. Background & Evolution

  • 1911: ICMR began. Its 115-year contribution was marked in 2026 [1].
  • DHR is the department under the Ministry of Health and Family Welfare. ICMR works under DHR [1].
  • 2024: Union Health Minister J P Nadda announced that DHR had completed its 100 Days Initiatives [8]. Separately, Nadda launched five health research initiatives under DHR-ICMR [7].
  • March 2025: Medical Innovations Patent Mitra was launched by Union Health Minister J P Nadda [1]. The launch took place at the third International Symposium on Health Technology Assessment (ISHTA 2025). Released alongside it were an Open Real-Time PCR Kit for pulmonary TB diagnosis, the HTA Technologies Compendium and the HTA Costing Database [2].
  • 2025: ICMR licensed nine technologies to industry partners at India MedTech Expo 2025 at Bharat Mandapam [3].
  • 2025: The Maha MedTech Mission was launched by ANRF together with ICMR and the Gates Foundation [9].
  • 2026: ICMR held the "Medical Innovations Patent Mitra: Innovators-to-Industry (I2I) Connect" event, described as India's largest biomedical innovation and technology transfer event [4]. It transferred three indigenous technologies at National Technology Day 2026 [5] and another three technologies for cancer and infectious diseases [6].
  • Nov 2026: The 100-deal milestone was reached at the 3rd Summit [1].

4. Core Static Facts

Item Fact
ICMR Apex body for formulating, coordinating and promoting biomedical research. Works under DHR, MoHFW. Started 1911 [1]
DHR Department of Health Research, under the Ministry of Health and Family Welfare [1]
Medical Innovations Patent Mitra ICMR's flagship initiative for transferring its patented innovations to industry. Launched March 2025 [1][2]
Technology transfer (licensing) Moving a technology from the research developer to industry through a licensing agreement [1]
Research to Action Vertical New DHR vertical (2026). Turns research evidence into decision-ready products for policy and programmes [1]
Syndromic surveillance Added under the DHR VRDL Scheme. Early-warning network across 70 VRDLs and IRDLs. Picks up outbreaks from symptom patterns without waiting for confirmed diagnoses [1]
VRDL / IRDL Virus Research and Diagnostic Laboratories / Infectious Disease Research & Diagnostic Laboratories [1]
AMR outputs ICMR AMR Annual Report (brings together national AMR evidence) and SOPs (standardise laboratory procedures) [1]
Extramural research Research done by partner institutions outside ICMR's own institutes. The opposite is intramural research [1]
SHINE Science and Health Innovation for the NextGen Explorers. For Grades 9-12 students in government, government-aided and private schools. Aims to build scientific temper and interest in biomedical careers [1]
ICMR-NIMR National Institute of Malaria Research. Golden Jubilee (50 years) in 2026 [1]

Key numbers: 100 deals · 20 licensing agreements · 8 technologies · 9 companies · 70 labs in the surveillance network · 600+ participants · 115 years of ICMR · 50 years of NIMR [1]

5. Multi-Dimensional Analysis

Scientific / Technological

  • Patent Mitra changes the incentive from "publish only" to patent and license, so public-funded research ends up as products [1].
  • Syndromic surveillance moves outbreak detection earlier. It flags clusters of symptoms before lab confirmation, which helps preparedness for Disease X and pandemics [1].
  • Linked tools for health technology assessment (HTA compendium, costing database) support evidence-based buying of technologies [2].

Economic

  • Licensing to Indian companies supports Atmanirbhar Bharat in MedTech and diagnostics and reduces dependence on imports [1][3].
  • Ties into the wider MedTech push: India MedTech Expo [3] and the Maha MedTech Mission [9].

Governance / Administrative

  • The Research to Action Vertical addresses the gap between evidence and policy. Research becomes decision-ready inputs for health programmes [1].
  • SOPs for AMR labs standardise quality across institutions, so data can be compared nationally [1].
  • Pending issues: how royalties are shared, whether licensing is exclusive or non-exclusive (which affects affordability), and how VRDL data connects with IDSP/IHIP.

Social / Public Health

  • Affordable indigenous diagnostics improve equitable access, for example the open RT-PCR kit for TB [2].
  • SHINE reaches students across school types (government, aided, private), building scientific temper (Art. 51A(h)) and a future biomedical workforce [1].

Ethical

  • Public-funded patents raise a question: should licensing aim to earn revenue or to maximise public access? The stated aim is "wider public use" [1].
  • AMR raises the problem of shared resources (a tragedy of the commons). Evidence reports support stewardship but do not enforce it [1].

6. Recent Developments (last 12-18 months)

  • 2025: Nine ICMR technologies licensed at India MedTech Expo 2025, Bharat Mandapam [3].
  • 2025: ANRF, ICMR and Gates Foundation launch the Maha MedTech Mission [9].
  • 2026: Patent Mitra I2I Connect event held in New Delhi [4].
  • 2026: Three indigenous medical technologies transferred at National Technology Day 2026 [5].
  • 2026: Three technologies for cancer and infectious diseases transferred [6].
  • 16-17 Nov 2026: 3rd DHR-ICMR Summit. 100-deal milestone, 20 agreements, Research to Action Vertical, syndromic surveillance in 70 labs, AMR Annual Report and SOPs, ICMR at 115 years, NIMR at 50 years [1].

7. Prelims Hooks

  • ICMR functions under DHR, Ministry of Health and Family Welfare [1].
  • ICMR started in 1911 and marked 115 years in 2026 [1].
  • Medical Innovations Patent Mitra was launched in March 2025 by Union Health Minister J P Nadda [1].
  • Patent Mitra was released at ISHTA 2025 (third International Symposium on Health Technology Assessment) [2].
  • ICMR crossed 100 technology transfer deals in less than 2 years of Patent Mitra [1].
  • At the 3rd Summit, 20 licensing agreements covering 8 technologies were exchanged with 9 Indian companies [1].
  • Syndromic surveillance was added under the DHR VRDL Scheme, covering 70 VRDLs and IRDLs [1].
  • Syndromic surveillance detects outbreaks from symptom patterns, not confirmed diagnoses [1].
  • The Research to Action Vertical is a DHR initiative (2026), not a NITI Aayog one [1].
  • SHINE stands for Science and Health Innovation for the NextGen Explorers and targets Grades 9-12 [1].
  • ICMR-NIMR is the malaria research institute. Golden Jubilee in 2026 [1].
  • Extramural research means research by partner institutions outside ICMR's own institutes [1].
  • Maha MedTech Mission: ANRF + ICMR + Gates Foundation [9].

8. What the 100-Deal Number Does Not Tell Us

  • A 'deal' is not a technology, and it is not a product in a hospital
  • At India MedTech Expo 2025, nine technologies produced 17 licensing deals [3]. One technology can be licensed to several companies, and each licence counts as a deal.
  • So the 100 deals stand for far fewer than 100 separate inventions [1][3].
  • None of the releases say how many licensed technologies have reached the market, at what price, or how many patients use them [1][5].

  • Licensing does not bring in much money for public labs

  • Royalty (the fee a company pays the inventor for using a patent) earned by NRDC, India's main government licensing body, was about Rs 324 lakh in 2023-24. It fell to Rs 82 lakh in 2024-25 and was Rs 93 lakh in 2025-26 [11].
  • That is very small next to DHR's budget of Rs 4,821 crore for 2026-27 [10].
  • The US saw the same thing. WIPO notes that university licensing income stays small compared with research funding, and that many technology transfer offices (the units that sell patents to industry) run at a loss [15].
  • So Patent Mitra should be judged by whether people get the products, not by deal counts or revenue.

9. Exclusive or Non-Exclusive: The Choice That Sets the Price

  • The type of licence decides who can make the product, and that decides the price
  • An exclusive licence lets only one company make the product, so that company controls the price.
  • A non-exclusive licence lets several companies make it, and competition between them keeps the price down.
  • The government told Parliament that public institutions license on both bases, guided by their institutional IP committees [11].
  • The summit release says 20 agreements were exchanged, but it does not say which type each one is [1]. A reader cannot check the stated aim of 'wider public use' [1].

  • India is following a US model whose results are still argued over

  • The US Bayh-Dole Act (1980) let universities own patents from government-funded research and give exclusive licences [15].
  • Licensing rose sharply afterwards. But studies cited by WIPO argue that much of this rise would have happened anyway, because US universities and industry were already closely linked [15].

10. The Strongest Case Against Selling Public Patents, and an Honest Answer

  • The objection: taxpayers pay twice
  • Public money pays for the research. Then the public pays a private company's price for the product.
  • Critics also warn that pressure to earn from licences pulls scientists away from basic research [15].

  • What the objection gets right

  • Licence terms are not made public, so nobody outside can check whether access is protected [1][11].
  • Revenue is small anyway [11], so earning money is a weak reason for the programme.

  • Where it goes wrong

  • A lab cannot make and sell a diagnostic kit across India. A company has to manufacture it, get regulatory approval and distribute it.
  • Without a licence, many patented inventions simply stay in the lab. Before Bayh-Dole, very few US government-owned patents were ever licensed to industry [15].

  • The balanced answer

  • The question is not whether to license but on what terms. For simple, fully public-funded diagnostics, an open or non-exclusive route is possible. ICMR already released an Open Real-Time PCR kit for TB [2].

11. Big New Tasks, Same Short-Staffed Labs

  • More work is being given to an organisation that is already short of scientists
  • The summit added a new vertical, surveillance in 70 labs, AMR reports and SOPs [1], on top of research and patenting.
  • 16% of ICMR's sanctioned scientist posts were vacant in 2023 [10][16].
  • In 2017, the Parliamentary Standing Committee on Health found ICMR's research output low and its staff strength too small for effective research [10][16].

  • The money has grown, but Parliament has said it is still not enough

  • ICMR gets 83% of DHR's 2026-27 budget, Rs 4,000 crore, up from 73% in 2024-25 [10].
  • In 2023, the Standing Committee said ICMR's research spending is not enough to deal with anaemia, cancer and hypertension [10][16].
  • In 2018, the Committee pointed to a 'huge, persistent and recurring' gap between the funds DHR asked for and the funds it got. In 2021 it recommended that health research get 5% of the Ministry's total spending [10][16].

12. Why India's Disease Data Still Sits in Separate Boxes

  • AMR data comes from two parallel government networks
  • AMR means antimicrobial resistance: germs that no longer respond to medicines.
  • ICMR runs the AMR Surveillance and Research Network (AMRSN) in 30 tertiary care hospitals, both government and private [13].
  • NCDC, under the same Ministry, runs a separate network called NARS-Net in state medical colleges [13].
  • Tertiary hospitals mostly treat the sickest patients, who are referred from elsewhere. Data from them alone can make the resistance picture look different from what happens in district hospitals and the community.

  • The national plan asks for more than lab reports

  • India's National Action Plan on AMR (NAP-AMR) was launched in April 2017 with a One Health approach (human, animal and environmental health treated together) [12].
  • The plan also asks for surveillance of antimicrobial use, meaning how much medicine is actually used, not just how much resistance shows up [12]. The summit's report and SOPs cover the laboratory side [1].
  • WHO's India page lists the plan's period as 2017-2021 [14]. Check the status of the follow-on plan before quoting it.

  • An early warning works only if someone acts on it

  • Syndromic surveillance in VRDLs creates signals before a diagnosis is confirmed [1].
  • Those signals are useful only if they reach the district teams that respond to outbreaks. Those teams work under a different programme, IDSP.

13. What DHR, ICMR and the Health Ministry Should Do Next

  • ICMR should publish a public register of every licence
  • For each deal it should show the technology, whether the licence is exclusive or not, the royalty terms, whether the product has launched, and its price.
  • Royalty figures are already reported to Parliament for NRDC [11], so this kind of reporting can be done.

  • DHR should make non-exclusive the default for fully public-funded diagnostics

  • The precedent already exists: ICMR's Open Real-Time PCR kit for TB [2].
  • Exclusive licences can be kept for devices that need heavy company investment, with a clear reason recorded for each.

  • The Health Ministry should act on the Standing Committee's advice

  • Fill vacant scientist posts and move health research towards 5% of Ministry spending, as the Committee recommended in 2021 [10][16].

  • ICMR and NCDC should combine their AMR data

  • Merge AMRSN and NARS-Net results into one national dataset [13] that also tracks how much medicine is used, as NAP-AMR requires [12].
  • Send VRDL syndromic signals straight into IHIP, so that a warning leads to a district response.

14. Anchors for Answers

  • Data: DHR budget 2026-27 is Rs 4,821 crore, and ICMR gets 83% of it (Rs 4,000 crore) [10]
  • Data: 16% of ICMR's sanctioned scientist posts were vacant in 2023 [10][16]
  • Data: NRDC royalty income fell from about Rs 324 lakh (2023-24) to Rs 93 lakh (2025-26). This shows licensing is not a big earner [11]
  • Data: 9 technologies gave 17 licensing deals at MedTech Expo 2025, so deals are more than technologies [3]
  • Report/Committee: Parliamentary Standing Committee on Health. It found ICMR's output low (2017), a persistent funding gap (2018), recommended 5% of Ministry spending for research (2021), and said spending is not enough for anaemia, cancer and hypertension (2023) [10][16]
  • Law/Case: Article 51A(h) (scientific temper). Patents Act 1970 (licensing and compulsory licensing frame how public patents can be used)
  • Comparison: US Bayh-Dole Act 1980. It let universities own and exclusively license publicly funded inventions. Licensing rose, but income stayed small and many transfer offices ran at a loss [15]
  • Scheme: National Action Plan on AMR (2017, One Health). It covers both resistance and antimicrobial-use surveillance [12]. ICMR's AMRSN and NCDC's NARS-Net are the two lab networks [13]

15. Mains Relevance

16. Related Topics to Study Next

  • Anusandhan National Research Foundation (ANRF): the new apex body for research funding; partner in the Maha MedTech Mission [9].
  • Health Technology Assessment in India (HTAIn) / ISHTA: the platform where Patent Mitra was launched [2].
  • National Action Plan on AMR and One Health: context for the ICMR AMR report and SOPs.
  • IDSP / IHIP: India's integrated disease surveillance system, which syndromic surveillance should connect with.
  • National Medical Devices Policy and PLI for MedTech: the industry side of technology licensing.
  • IPR regime (Patents Act 1970, Section 3(d), compulsory licensing): frames how public patents are licensed.
  • National Centre for Vector Borne Diseases Control and malaria elimination: links to the NIMR Golden Jubilee.
  • Origin of ICMR (IRFA, 1911): background for its 115-year history (check this against ICMR's own history page).

17. NCERT Concepts to Revise

  • Indian Council of Medical Research (Polity): ICMR is the apex biomedical research body whose deals, initiatives and capacity the whole summit note is about.
  • Department of Health Research (Polity): DHR is the parent department under which ICMR works, and it launched the Research to Action Vertical and surveillance.
  • Technology transfer (Economy): The headline result is 100 technology transfer deals moving ICMR inventions to Indian companies.
  • Patent (Economy): Patent Mitra transfers ICMR's patented inventions, so you need to know what a patent gives the holder.
  • Intellectual property rights (Economy): Licensing public patents, exclusive versus non-exclusive terms and the Bayh-Dole comparison all rest on IPR basics.
  • Compulsory licensing (Economy): It is the legal tool the note names for how public patents can be used for public health.
  • Antimicrobial resistance (Geography): The summit released ICMR's AMR Annual Report and SOPs, so you need to understand the problem itself.
  • National Action Plan on AMR (Economy): India's national policy on AMR, with its One Health approach, frames the new report and lab standards.
  • One Health (Geography): NAP-AMR uses this approach of treating human, animal and environmental health together.
  • Scientific temper (Polity): The SHINE programme for school students builds scientific temper, a duty under Article 51A(h).
  • Atmanirbhar Bharat (Economy): Licensing to Indian companies is meant to cut import dependence in MedTech and diagnostics.
  • Anusandhan National Research Foundation (Polity): ANRF is the new apex research funder and a partner in the Maha MedTech Mission.
  • Biological disasters (Geography): Syndromic surveillance aims at early outbreak warning and preparedness for epidemics and pandemics.
  • Malaria elimination (Economy): ICMR-NIMR's Golden Jubilee links the summit to India's malaria elimination work.

18. Common Errors / Trap Areas

  • DHR vs ICMR: DHR is the department. ICMR is the research body under it. Both sit under MoHFW, not the Ministry of Science & Technology or DST/DBT [1].
  • VRDL vs IRDL: VRDL means Virus labs. IRDL means Infectious Disease labs. The 70-lab figure covers both together [1].
  • Number mix-ups: 100 is the cumulative number of deals. 20 is the number of agreements at the 2026 ceremony. 8 technologies and 9 companies [1]. Don't confuse these with the nine technologies licensed at India MedTech Expo 2025 [3].
  • "Syndromic" ≠ "lab-confirmed" surveillance. Syndromic surveillance works on symptom patterns before diagnosis [1].
  • Anniversaries: 115 years belongs to ICMR, and 50 years to ICMR-NIMR. Don't mix them up [1]. Also, "Patent Mitra" (ICMR, patents and licensing) is a different thing from "MedTech Mitra" (regulatory and market-access support).

Sources

  1. 13rd DHR-ICMR Health Research Excellence Summit (PIB release digest provided by user)pib.gov.in · tier 1
  2. 2Union Health Minister Shri JP Nadda inaugurates third International Symposium on Health Technology Assessment 2025pib.gov.in · tier 1
  3. 3ICMR Licenses Nine Breakthrough Health Technologies to Industry Partners at India MedTech Expo 2025pib.gov.in · tier 1
  4. 4ICMR organizes India's largest biomedical innovation and technology transfer event "Medical Innovations Patent Mitra: Innovators-to-Industry (I2I) Connect"pib.gov.in · tier 1
  5. 5ICMR transfers three Indigenous Medical Technologies to Industry at National Technology Day 2026pib.gov.in · tier 1
  6. 6ICMR transfers three indigenous biomedical technologies to advance cancer and infectious disease solutionspib.gov.in · tier 1
  7. 7Union Health Minister Shri JP Nadda Launches Five Pioneering Health Research Initiatives under DHR-ICMRpib.gov.in · tier 1
  8. 8Union Health Minister announces successful implementation of 100 Days Initiatives by the Department of Health Researchpib.gov.in · tier 1
  9. 9ANRF, in collaboration with ICMR and Gates Foundation, launches Maha MedTech Missionpib.gov.in · tier 1
  10. 10Demand for Grants 2026-27 Analysis: Health and Family Welfare (PRS Legislative Research)prsindia.org · tier 1
  11. 11Parliament Question: Commercialisation and Transfer of Government-Developed Technologiespib.gov.in · tier 1
  12. 12National Action Plan on Antimicrobial Resistance (India), WHO NAP library — ).pdf?sfvrsn=9f396e90_1&download=truecdn.who.int · tier 2
  13. 13Measures taken to address challenges posed by anti-microbial resistance (AMR) in Indiapib.gov.in · tier 1
  14. 14Antimicrobial Resistance, WHO India health topicswho.int · tier 2
  15. 15World Intellectual Property Report 2011, Chapter 4: Harnessing Public Research for Innovationwipo.int · tier 2
  16. 16Demand for Grants 2025-26 Analysis: Health and Family Welfare (PRS Legislative Research)prsindia.org · tier 1

Mains Q&A on this note

NCERT concepts in this note

Also on 18 November

All 18 November articles →